Novo gets US backing for Victoza cardiovascular data
US regulatory advisors are backing the claim that Novo Nordisk’s Victoza reduces cardiovascular risk in patients with diabetes.
Read More
Tag: cardiovascular death
FDA allows cardiovascular death reduction claim for Jardiance
In a huge boon for Lilly and Boehringer Ingelheim, US regulators have expanded the scope of diabetes drug Jardiance to include a reduction in the risk of cardiovascular death patients with type II forms of the condition and cardiovascular disease.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
